Enhancement of melphalan-induced gastrointestinal toxicity in mice treated with regional hyperthermia and BSO-mediated glutathione depletion

References

• Bullard D. E., Schold S. C., Jr, Bigner S. H., Bigner D. D. Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines. Journal of Neuropathology and Experimental Neurology 1981; 40: 410–427
   PubMed Web of Science ®Google Scholar
• Cope D. A., Dewhirst M. W., Friedman H. S., Bigner D. D., Zalutsky M. R. Enhanced delivery of a monoclonal antibody F(ab')2 fragment to subcutaneous human glioma xenografts using local hyperthermia. Cancer Research 1990; 50: 1803–1809
   PubMed Web of Science ®Google Scholar
• Dorr R. T., Liddil J. D., Soble M. J. Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells. Investigational New Drugs 1986; 4: 305–313
   PubMed Web of Science ®Google Scholar
• Friedman H. S., Colvin O. M., Aisaka K., Popp J., Bossen E. H., Reimer K. A., Powell J. B., Hilton J., Gross S. S., Levi R., Bigner D. D., Griffith O. W. Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity. Cancer Research 1990; 50: 2455–2462
   PubMed Web of Science ®Google Scholar
• Friedman H. S., Schold S. C., Jr, Varia M., Bigner D. D. Chemotherapy and radiation therapy of human medulloblastoma in athymic nude mice. Cancer Research 1983; 43: 3088–3093
   PubMed Web of Science ®Google Scholar
• Friedman H. S., Schold S. C., Jr, Bigner D. D. Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice. Cancer Research 1986; 46: 224–228
   PubMed Web of Science ®Google Scholar
• Friedman H. S., Schold S. C., Jr, Mahaley M. S., Jr, Colvin O. M., Oakes W. J., Vick N. A., Burger P. C., Bigner S. H., Borowitz M., Halperin E. C., Djang W., Falletta J. M., DeLong R., Garvin J. H., DeVivo D. C., Norris D., Golembe B., Winter J., Bodziner R. A., Sipahi H., Bigner D. D. Phase II treatment of medulloblastoma and pineoblastoma with melphalan: clinical therapy based on experimental models of human medulloblastoma. Journal of Clinical Oncology 1989; 7: 904–911
   PubMed Web of Science ®Google Scholar
• Goldfeder A., Neubort S. Thermally-enhanced tumor regression in mice treated with melphalan. Anticancer Research 1984; 4: 17–22
   PubMed Web of Science ®Google Scholar
• Greco C., Cavaliere R., Giovanella B., Natali P. G., Zupi G. Effect of sequential application of hyperthermia and chemotherapy on the survival of a thermoresistant human melanoma cell line. Cancer Biochemical Biophysics 1987; 9: 223–232
   PubMedGoogle Scholar
• Griffith O. W. Mechanism of action, metabolism and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. Journal of Biological Chemistry 1982; 257: 13704–13712
   PubMed Web of Science ®Google Scholar
• Griffith O. W., Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). Journal of Biological Chemistry 1979; 254: 7558–7560
   PubMed Web of Science ®Google Scholar
• Hill B. T. Collateral sensitivity and cross-resistance. Handbook of Experimental Pharmacology, B. W. Fox, M. Fox. Springer-Verlag, Berlin 1984; vol. 72: 673–693
   Google Scholar
• Honess D. J., Donaldson J., Workman P., Bleehen N. M. The effect of systemic hyperthermia on melphalan pharmacokinetics in mice. British Journal of Cancer 1985; 51: 77–84
   PubMed Web of Science ®Google Scholar
• Horowitz M. E., Etcubanas E., Christensen M. L., Houghton J. A., George S. L., Green A. A., Houghton P. J. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. Journal of Clinical Oncology 1988; 6: 308–314
   PubMed Web of Science ®Google Scholar
• Kramer R. A., Greene K., Ahmad S., Vistica D. T. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine. Cancer Research 1987; 47: 1593–1597
   PubMed Web of Science ®Google Scholar
• Laskowitz D. T., Elion G. B., Dewhirst M. W., Griffith O. W., Casero R. A., Jr, Scott P. A., Bigner D. D., Friedman H. S. Effects of glutathione or polyamine depletion on in vivo thermosensitization. 1991a, (Submitted)
   Google Scholar
• Laskowitz D. T., Elion G. B., Dewhirst M. W., Griffith O. W., Savina P. M., Blum M. R., Prescott D. A., Bigner D. D., Friedman H. S. Hyperthermiainduced enhancement of melphalan activity against human rhabdomyosarcoma xenografts. 1991b, (Submitted)
   Google Scholar
• Martensson J., Jain A., Meister A. Glutathione is required for intestinal function. Proceedings of the National Academy of Sciences, USA 1990; 87: 1715–1719
   PubMed Web of Science ®Google Scholar
• Mc Allister R. M., Isaacs H., Rongey R., Peer M., Au W., Soukup S. W., Gardner M. B. Establishment of a human medulloblastoma cell line. International Journal of Cancer 1977; 20: 206–212
   PubMed Web of Science ®Google Scholar
• O'Hara M. D., Hetzel F. W., Frinak S. Thermal distributions in a water bath heated mouse tumor. International Journal of Radiation Oncology, Biology, and Physics 1985; 11: 817–822
   PubMed Web of Science ®Google Scholar
• Page R. L., Thrall D. E., Dewhirst M. W., Macy D. W., George S. L., Mc Entee M. C., Heidner G. L., Novotney C. A., Allen S. A., Withrow S. J., Ogilvie G. K., Gilette E. L. Phase I study of melphalan alone and melphalan plus whole-body hyperthermia in dogs with malignant melanoma. International Journal of Hyperthermia 1991; 7: 559–566
   PubMed Web of Science ®Google Scholar
• Pritchard J., Mc Elwain T. J., Graham-Pole J. High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma. British Journal of Cancer 1982; 45: 86–94
   PubMed Web of Science ®Google Scholar
• Rosenberg M. C., Colvin O. M., Griffith O. W., Bigner S. H., Elion G. B., Horton J. K., Lilley E., Bigner D. D., Friedman H. S. Establishment of a melphalan-resistant human rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion. Cancer Research 1989; 49: 6917–6922
   PubMed Web of Science ®Google Scholar
• Sarosy G., Leyland-Jones B., Soochan P., Cheson B. D. The systemic administration of intravenous melphalan. Journal of Clinical Oncology 1988; 6: 1768–1782
   PubMed Web of Science ®Google Scholar
• Skapek S. X., Colvin O. M., Griffith O. W., Elion G. B., Bigner D. D., Friedman H. S. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice. Cancer Research 1988; 48: 2764–2767
   PubMed Web of Science ®Google Scholar
• Skapek S. X., Vandellen A. F., Mc Mahon D. P., Postels D. G., Griffith O. W., Bigner D. D., Friedman H. S. Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine. Cancer Chemotherapy and Pharmacology 1991; 28: 15–21
   PubMed Web of Science ®Google Scholar
• Smith A. C., Liao J. T. F., Page J. G., Wientjes M. G., Grieshaber C. K. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice. Cancer Research 1989; 49: 5385–5391
   PubMed Web of Science ®Google Scholar
• Smith J. P., Rutledge F., Wharton J. T. Chemotherapy of ovarian cancer. New approaches to treatment. Cancer 1972; 30: 1565–1571
   PubMed Web of Science ®Google Scholar
• Stratton M. R., Darling J., Pilkington G. J., Lantos P. L., Reeves B. R., Cooper C. S. Characterization of the human cell line TE671. Carcinogenesis 1989; 10: 899–905
   PubMed Web of Science ®Google Scholar
• Werts E. D., Smith K. M. Temporal response of murine bone marrow to local hyperthermia. International Journal of Radiation Oncology, Biology, and Physics 1984; 10: 2315–2321
   PubMed Web of Science ®Google Scholar